The antitumor activity of thymoquinone and thymohydroquinone in vitro and in vivo

Experimental Oncology

Volumn 28, Issue 3, 2006, Pages 220-224

  Ivankovic, S ^a   Stojkovic, R ^a   Jukic, M ^b   Milos, M ^b,c   Jurin, M ^a  

^a RUDER BO KOVI INSTITUTE   (Croatia)

^b UNIVERSITY OF SPLIT   (Croatia)

^c UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Antitumor activity; In vitro; In vivo; Mice; Thymohydroquinone; Thymoquinone

Indexed keywords

ANTINEOPLASTIC AGENT; CRYSTAL VIOLET; HYDROQUINONE DERIVATIVE; THYMOHYDROQUINONE; THYMOQUINONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFICACY; FIBROBLAST; FIBROSARCOMA; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; SQUAMOUS CELL CARCINOMA; STAINING; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZOQUINONES; CELL LINE, TUMOR; FIBROBLASTS; MALE; MICE; MICE, INBRED STRAINS; NEOPLASMS; THYMOL;

EID: 33750944928     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Stojkovic R, Radacic M. Cell killing of melanoma B16 by hyperthermia and cytotoxins. Int J Hyperther 2002; 18: 62-71.
2. Apryshko GA, Ivanov VN, Milchakova NA, Nekhoroshev MV. Mediterranean and black sea organisms and algae from mariculture as sources of antitumor drugs. Exp Oncol 2005; 2: 94-5.
3. Xie JT, Wang CZ, Wicks S, Yin JJ, Kong J, Li J, Li YC, Yuan CS. Ganoderma lucidum extract inhibits proliferation of SW 480 human colorectal cancer cells. Exp Oncol 2006; 28: 25-9.
4. Stojkovic R, Karminski-Zamola G, Racane L, Tralic-Kulenovic V, Glavas-Obrovac L, Ivankovic S, Radacic M. Antitumor efficiency of novel fluoro-substituted 6-amino-2-phenylbenzothiazole hydrochloride salts in vitro and in vivo. Methods Find Exp Clin Pharmacol 2006; 28: 347-54.
5. Xu G, Liang Q, Gong Z, Yu W, He S, Xi L. Antitumor activities of the foursesquiterpene lactones from Elephantopus scaber L. Exp Oncol 2006; 28: 106-9.
6. Ali BH, Blunden G. Pharmacological and toxicological properties of Nigella sativa. Phytother Res 2003; 17: 299-305.
7. Gali-Muhtasib H, Schneider-Stock R. The medicinal potential of black seed (Nigella sativa) and its components. In: New trends in research strategies on lead molecules from natural products. Kheir LA, ed. Amsterdam: Elsevier, 2004.
8. El-Dakhakhny M. Studies on the chemical constituents of Egyptian Nigella sativa L. seeds. The essential oil. Planta Med 1963; 11: 465-70.
9. Lee WR. Schwarzkummelol. Dtsch Apoth Ztg 1997; 137: 68-9.
10. Badary OA, Al-Shabanah OA, Nagi MN, Al-Rikabi AC, Elmazar MM. Inhibition of benzo(a)pyrene-induced forestomach carcinogenesis in mice by thymoquinone. Eur J Cancer Prev 1999; 8: 435-40.
11. Salomi MJ, Nair SC, Panikkar KR. Inhibitory effects of Nigella sativa and saffron (Crocus sativus) on chemical carcinogenesis in mice. Nutr Cancer 1991; 16: 67-72.
12. Gali-Muhtasib HU, Abou Kheir WG, Kheir LA, Darwiche N, Crooks PA. Molecular pathway for thymoquinone-induced cell-cycle arrest and apoptosis in neoplastic keratinocytes. Anticancer Drugs 2004; 15: 389-99.
13. Badary OA. Thymoquinone attenuates ifosfamide-induced Fanconi syndrome in rats and enhances its antitumor activity in mice. J Ethnopharmacol 1999; 67: 135-42.
14. Nair SC, Salomi MJ, Panikkar B, Panikkar KR. Modulatory effects of Crocus sativus and Nigella sativa extracts on cisplatininduced toxicity in mice. J Ethnopharmacol 1991; 31: 75-83.
15. Salomi NJ, Nair SC, Jayawardhanan KK, Varghese CD, Panikkar KR. Antitumour principles from Nigella saliva seeds. Cancer Lett 1992; 63: 41-6.
16. Worthen DR, Ghosheh OA, Crooks PA. The in vitro anti-tumor activity of some crude and purified components of blackseed, Nigella sativa L. Anticancer Res 1998; 18: 1527-32.
17. Marsik P, Kokoska L, Landa P, Nepovim A, Soudek P, Vanek T. In vitro inhibitory effects of thymol and quinones of Nigella sativa seeds on cyclooxygenase-1 - and -2-catalyzed prostaglandin E2 biosyntheses. Planta Medica 2005; 71: 739-42.
18. Kremers E, Wakeman N, Hixon RM. Thymoquinone. Organic Syntheses. Collective Volume 1941; 1: 511-5.
19. Stolow RD, McDonagh PM, Bonaventura MM. Conformational studies. VI. Intramolecular hydrogen bonding in non-chair conformations of cis,cis,cis-2,5-dialkyl-1,4-cyclohexanediols. J Am Chem Soc 1964; 86: 2165-70.
20. El-Dakhakhny M. Studies on the Egyptian Nigella sativa L. IV. Some pharmacological properties of the seeds' active principle in comparison to its dihydro compound and its polymer. Arzneimittelforschung 1965; 15: 1227-9.
21. Teicher BA. In vivo tumor response end points. In: Tumor Models in Cancer Research. Ticher BA, ed. Humana Press Inc.: Totowa, New Jersey, 2002; 593-616.
22. Shoieb AM, Elgayyar M, Dudrick PS, Bell JL, Tithof PK. In vitro inhibition of growth and induction of apoptosis in cancer cell lines by thymoquinone. Int J Oncol 2003; 22: 107-13.
23. Shoieb AM, Hahn KA, Barnhill MA. An in vivo/in vitro experimental model system for the study of human osteosarcoma: canine osteosarcoma cells (COS31) which retain osteoblastic and metastatic properties in nude mice. In Vivo 1998; 12: 463-72.
24. Gali-Muhtasib H, Diab-Assaf M, Boltze C, Al-Hmaira J, Hartig R, Roessner A, Schneider-Stock R. Thymoquinone extracted from black seed triggers apoptotic cell death in human colorectal cancer cells via a p53-dependent mechanism. Int J Oncol 2004; 25: 857-66.
25. Schimming R, Kathryn AM, Hunter N, Weil M, Kishi K, Milas L. Lack of correlation betwen mitotic arrest of apoptosis and antitumor effect of docetaxel. Cane chemoth Pharmacol 1999; 43: 165-72.